Immune characterization of breast cancer metastases: prognostic implicationsMaria Vittoria Dieci, Valentina Guarneri, Vassilena Tsvetkova et al.|Breast Cancer Research|2018Cited by 89
Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I–III patients treated with standard therapyMaria Vittoria Dieci, PierFranco Conte, Vassilena Tsvetkova et al.|European Journal of Cancer|2020Cited by 74
Androgen Receptor Expression and Association With Distant Disease-Free Survival in Triple Negative Breast Cancer: Analysis of 263 Patients Treated With Standard Therapy for Stage I-III DiseaseMaria Vittoria Dieci, Valentina Guarneri, Vassilena Tsvetkova et al.|Frontiers in Oncology|2019Cited by 71
HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trialValentina Guarneri, Aleix Prat, Charles M. Perou et al.|EBioMedicine|2022Cited by 42
Prognostic factors in phyllodes tumours of the breast: retrospective study on 166 consecutive casesElisabetta Di Liso, Valentina Guarneri, Michele Bottosso et al.|ESMO Open|2020Cited by 33